DC-159a 是一种新型氟喹诺酮类药物，对分枝杆菌属的体外活性。
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
机构信息
Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Kiyose, Tokyo 204-8533, Japan.
出版信息
Antimicrob Agents Chemother. 2010 Jun;54(6):2684-6. doi: 10.1128/AAC.01545-09. Epub 2010 Apr 5.
Abstract
The in vitro activities of DC-159a against seven species of Mycobacterium were compared with moxifloxacin, gatifloxacin, levofloxacin, and rifampin. DC-159a was the most active compound against quinolone-resistant multidrug-resistant M. tuberculosis (MIC(90), 0.5 microg/ml) as well as drug-susceptible isolates (MIC(90), 0.06 microg/ml). The anti-tubercle bacilli activity of DC-159a was 4- to 32-fold more potent than those of currently available quinolones. DC-159a also demonstrated the highest activities against clinically important nontuberculous mycobacteria.
摘要
将 DC-159a 与莫西沙星、加替沙星、左氧氟沙星和利福平进行比较，评估其对 7 种分枝杆菌的体外活性。DC-159a 对耐氟喹诺酮类药物的多重耐药结核分枝杆菌（MIC90，0.5μg/ml）以及药敏分离株（MIC90，0.06μg/ml）最为有效。DC-159a 的抗结核分枝杆菌活性比目前可用的氟喹诺酮类药物强 4 至 32 倍。DC-159a 对临床重要的非结核分枝杆菌也具有最高的活性。
相似文献
1
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.DC-159a 是一种新型氟喹诺酮类药物，对分枝杆菌属的体外活性。
Antimicrob Agents Chemother. 2010 Jun;54(6):2684-6. doi: 10.1128/AAC.01545-09. Epub 2010 Apr 5.
2
In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.新型异噻唑酮喹诺酮 ACH-702 对结核分枝杆菌和其他分枝杆菌的体外活性。
Antimicrob Agents Chemother. 2010 May;54(5):2188-90. doi: 10.1128/AAC.01603-09. Epub 2010 Mar 15.
3
In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria.氟喹诺酮 DC-159a 对分枝杆菌的体外和体内活性。
J Antibiot (Tokyo). 2024 May;77(5):306-314. doi: 10.1038/s41429-024-00709-3. Epub 2024 Mar 4.
4
In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.新型氟喹诺酮类药物和利奈唑胺对非结核分枝杆菌的体外活性
Int J Antimicrob Agents. 2003 Jun;21(6):585-8. doi: 10.1016/s0924-8579(03)00048-7.
5
Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.分枝杆菌性角膜炎的局部抗菌治疗：手术预防和治疗的潜力
Clin Ther. 2004 Feb;26(2):191-6. doi: 10.1016/s0149-2918(04)90018-5.
6
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.新合成喹诺酮WQ-3034、左氧氟沙星、司帕沙星和环丙沙星对结核分枝杆菌和鸟分枝杆菌复合体的抗菌活性比较
Antimicrob Agents Chemother. 2000 Feb;44(2):283-6. doi: 10.1128/AAC.44.2.283-286.2000.
7
Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone.结核分枝杆菌对新型呼吸喹诺酮 DC-159a 的特征性耐药机制。
Antimicrob Agents Chemother. 2011 Aug;55(8):3958-60. doi: 10.1128/AAC.00417-10. Epub 2011 May 9.
8
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.氟喹诺酮类药物对结核分枝杆菌的体外活性。
J Chemother. 2005 Apr;17(2):169-73. doi: 10.1179/joc.2005.17.2.169.
9
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.gyrB基因突变在泰国临床分离株的广泛耐药和超级耐药结核病中的作用
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5189-97. doi: 10.1128/AAC.00539-16. Print 2016 Sep.
10
Induction of mycobacterial resistance to quinolone class antimicrobials.诱导分枝杆菌对喹诺酮类抗菌药物的耐药性。
Antimicrob Agents Chemother. 2012 Jul;56(7):3879-87. doi: 10.1128/AAC.00474-12. Epub 2012 May 7.
引用本文的文献
1
Advances in antibacterial agents for .用于……的抗菌剂的进展
RSC Med Chem. 2024 Oct 18;16(1):37-49. doi: 10.1039/d4md00508b.
2
In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria.氟喹诺酮 DC-159a 对分枝杆菌的体外和体内活性。
J Antibiot (Tokyo). 2024 May;77(5):306-314. doi: 10.1038/s41429-024-00709-3. Epub 2024 Mar 4.
3
Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.结核病关键药物靶标鉴定与新药研发进展。
Biomed Res Int. 2022 Feb 25;2022:5099312. doi: 10.1155/2022/5099312. eCollection 2022.
4
Mycobacterium abscessus drug discovery using machine learning.利用机器学习发现脓肿分枝杆菌药物。
Tuberculosis (Edinb). 2022 Jan;132:102168. doi: 10.1016/j.tube.2022.102168. Epub 2022 Jan 20.
5
Current Molecular Therapeutic Agents and Drug Candidates for .当前用于……的分子治疗剂和候选药物
Front Pharmacol. 2021 Aug 30;12:724725. doi: 10.3389/fphar.2021.724725. eCollection 2021.
6
Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.呈现处于不同药物研发阶段的新型抗结核药物的化学类别：2010 - 2020年综述
Pharmaceuticals (Basel). 2021 May 13;14(5):461. doi: 10.3390/ph14050461.
7
Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.抗分枝杆菌小分子药物研发管道：再利用药物和有前途的新型化学实体。
Med Res Rev. 2021 Jul;41(4):2350-2387. doi: 10.1002/med.21798. Epub 2021 Mar 1.
8
: Environmental Bacterium Turned Clinical Nightmare.环境细菌演变成临床噩梦
Microorganisms. 2019 Mar 22;7(3):90. doi: 10.3390/microorganisms7030090.
9
NTM drug discovery: status, gaps and the way forward.NTM 药物发现：现状、差距和未来发展方向。
Drug Discov Today. 2018 Aug;23(8):1502-1519. doi: 10.1016/j.drudis.2018.04.001. Epub 2018 Apr 7.
10
Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis.靶向DNA复制与修复以开发抗结核病新型疗法
Front Mol Biosci. 2017 Nov 14;4:75. doi: 10.3389/fmolb.2017.00075. eCollection 2017.
本文引用的文献
1
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.抗结核新药：临床研发中的问题、进展及药物评估
Antimicrob Agents Chemother. 2009 Mar;53(3):849-62. doi: 10.1128/AAC.00749-08. Epub 2008 Dec 15.
2
Minimising moxifloxacin resistance with tuberculosis.降低结核病对莫西沙星的耐药性
Lancet Infect Dis. 2008 May;8(5):273-5. doi: 10.1016/S1473-3099(08)70077-X.
3
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.一项关于氧氟沙星、加替沙星和莫西沙星对肺结核杀菌活性的II期研究。
Int J Tuberc Lung Dis. 2008 Feb;12(2):128-38.
4
In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone.新型氟喹诺酮类药物DC-159a的体外和体内抗菌活性
Antimicrob Agents Chemother. 2008 Jan;52(1):65-76. doi: 10.1128/AAC.00853-07. Epub 2007 Oct 15.
5
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.新型广谱氟喹诺酮类药物DC-159a与其他药物相比，对药敏和耐药肺炎球菌的体外活性。
Antimicrob Agents Chemother. 2008 Jan;52(1):77-84. doi: 10.1128/AAC.01229-07. Epub 2007 Oct 15.
6
Gatifloxacin in combination with rifampicin in a murine tuberculosis model.加替沙星与利福平联合用于小鼠结核病模型的研究
J Antimicrob Chemother. 2007 Aug;60(2):429-32. doi: 10.1093/jac/dkm200. Epub 2007 Jun 8.
7
Fluoroquinolones as chemotherapeutics against mycobacterial infections.氟喹诺酮类作为抗分枝杆菌感染的化疗药物。
Curr Pharm Des. 2004;10(26):3213-20. doi: 10.2174/1381612043383296.
8
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.含莫西沙星的治疗方案可显著缩短小鼠结核病培养转阴时间。
Am J Respir Crit Care Med. 2004 Feb 1;169(3):421-6. doi: 10.1164/rccm.200310-1380OC. Epub 2003 Oct 24.
9
Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria.加替沙星和环丙沙星对四种快速生长分枝杆菌菌株的体外活性比较。
Antimicrob Agents Chemother. 2002 Oct;46(10):3283-5. doi: 10.1128/AAC.46.10.3283-3285.2002.
10
Activity of moxifloxacin against mycobacteria.莫西沙星对分枝杆菌的活性。
J Antimicrob Chemother. 1999 Sep;44(3):393-5. doi: 10.1093/jac/44.3.393.
Zotero 插件